2024-10-31 14:25 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association |
2024-10-30 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results |
2024-10-30 16:02 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology |
2024-10-21 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 |
2024-08-12 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results |
2024-08-12 16:01 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors |
2024-08-08 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System |
2024-08-01 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences |
2024-07-29 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 |
2024-07-08 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX(TM) nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation |
2024-07-03 14:44 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Announces the Closing of its Rights Offering |
2024-06-28 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering |
2024-05-20 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 |
2024-05-16 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA(TM)) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting |
2024-05-14 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Enhances Executive Leadership Team |
2024-05-09 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System |
2024-05-07 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results |
2024-05-02 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 |
2024-04-24 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 |
2024-03-28 16:12 | UU:PLSE | | News Release200 | Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results |
2024-03-28 16:10 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Plans to Initiate a Rights Offering |
2024-03-14 16:05 | UU:PLSE | | News Release200 | Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 |
2024-03-08 13:17 | UU:PLSE | | News Release200 | Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX(TM) nsPFA(TM) Percutaneous Electrode System |
2024-02-14 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX ‚ ® nsPFA ¢ „ ¢ 360 ‚ ° Cardiac Catheter First-in-Human Feasibility Study |
2024-01-31 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium |
2024-01-02 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX ‚ ® nsPFA ¢ „ ¢ Cardiac Clamp |
2023-12-20 08:00 | UU:PLSE | | News Release200 | Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX ¢ „ ¢ Nanosecond Pulsed Field Ablation (nsPFA ¢ „ ¢) Cardiac Catheter |